Catalyst Wire Dossier Catalyst Wire Dossier

Glyceryl tri-(4-phenylbutyrate)

Glyceryl tri-(4-phenylbutyrate) · Amgen
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Glyceryl tri-(4-phenylbutyrate), covering 2024-06-20 to 2024-06-20. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Glyceryl Tri-(4-phenylbutyrate) Administered Orally as a Single Dose, and Twice Daily for Seven Consecutive Days to Subjects With Hepatic Impairment With Cirrhosis and to a Control Group [Phase 1]

See pricing